TNF-α Inhibitors Are Safe for Breastfeeding in Psoriasis
TNF-α inhibitors (etanercept, adalimumab, infliximab, certolizumab pegol) are safe during lactation and should be your first-line biologic choice for treating psoriasis in breastfeeding mothers 1.
Primary Recommendation
The 2019 Joint AAD-NPF Guidelines explicitly state that TNF-α inhibitors are safe during lactation 1. This represents the highest-quality guideline evidence available and should guide your prescribing decisions. Among TNF-α inhibitors, certolizumab pegol has a theoretical advantage due to its unique molecular structure showing minimal to no placental transfer 1, though this property is more relevant during pregnancy than breastfeeding.
Practical Prescribing Algorithm
For breastfeeding mothers with psoriasis requiring biologics:
First choice: Any TNF-α inhibitor (etanercept, adalimumab, infliximab, certolizumab pegol) 1
- All have established safety profiles during lactation
- Certolizumab pegol may be preferred if future pregnancy is planned 2
Alternative options with emerging safety data:
- IL-12/23 inhibitor (ustekinumab)
- IL-17 inhibitors (secukinumab, ixekizumab)
- IL-23 inhibitors (guselkumab, risankizumab)
Recent pharmacovigilance data suggests these newer biologics may have comparable or even lower frequencies of adverse outcomes compared to TNF-α inhibitors 3, though specific lactation data remains limited 4, 5.
Critical Timing Considerations
Important caveat: If the mother received TNF-α inhibitors during pregnancy, the neonate should be considered immunosuppressed for 1-3 months postpartum (depending on the specific TNF inhibitor used) 1. This affects:
- Live vaccine administration timing in the infant
- Particularly relevant for BCG vaccine - exercise caution in the first year 6
- Standard vaccination schedules can proceed for non-live vaccines
Evidence Strength and Nuances
The guideline recommendation for TNF-α inhibitor safety during lactation 1 is based on:
- Long-established clinical experience (these drugs have been available longest)
- Consistent safety signals across multiple inflammatory conditions
- Minimal drug transfer into breast milk due to large molecular size
Newer biologics (IL-17, IL-23 inhibitors) have less robust lactation-specific data because they are newer agents 4, 5. However, 2024-2025 evidence suggests they may be equally safe 3, and their use should not be automatically excluded if there are compelling clinical reasons (such as superior efficacy for the individual patient or prior TNF-α inhibitor failure).
Common Pitfalls to Avoid
- Do not unnecessarily discontinue effective biologic therapy when a patient begins breastfeeding - the risks of untreated severe psoriasis to maternal quality of life often outweigh theoretical concerns
- Do not confuse pregnancy and lactation safety profiles - drugs contraindicated in pregnancy (like methotrexate) have different risk profiles than those used during breastfeeding
- Do not delay live vaccines in the infant beyond necessary - only the period of neonatal immunosuppression (1-3 months) requires caution, not the entire breastfeeding duration 1